KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has KalVista Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KALV's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: KALV exceeded the US Biotechs industry which returned 33.9% over the past year.
Return vs Market: KALV exceeded the US Market which returned 18.5% over the past year.
Price Volatility Vs. Market
How volatile is KalVista Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's What We Learned About The CEO Pay At KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
1 month ago | Simply Wall StIs KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
2 months ago | Simply Wall StHow Much Are KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insiders Spending On Buying Shares?
Is KalVista Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: KALV ($16.95) is trading above our estimate of fair value ($3.03)
Significantly Below Fair Value: KALV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: KALV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: KALV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KALV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KALV is overvalued based on its PB Ratio (4.1x) compared to the US Biotechs industry average (3.4x).
How is KalVista Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KALV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KALV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KALV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KALV's revenue (65.1% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: KALV's revenue (65.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KALV's Return on Equity is forecast to be high in 3 years time
How has KalVista Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KALV is currently unprofitable.
Growing Profit Margin: KALV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KALV is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare KALV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KALV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: KALV has a negative Return on Equity (-43.79%), as it is currently unprofitable.
How is KalVista Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: KALV's short term assets ($80.2M) exceed its short term liabilities ($8.5M).
Long Term Liabilities: KALV's short term assets ($80.2M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: KALV is debt free.
Reducing Debt: KALV has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KALV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KALV has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 27.3% each year.
What is KalVista Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KALV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KALV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KALV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KALV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KALV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andy Crockett (45 yo)
Mr. Thomas Andrew Crockett, also known as Andy, M.B.A., has been Chief Executive Officer and Director of KalVista Pharmaceuticals, Inc. since November 21, 2016. Mr. Crockett is the Founder of KalVista Pha ...
CEO Compensation Analysis
Compensation vs Market: Andy's total compensation ($USD1.73M) is about average for companies of similar size in the US market ($USD1.93M).
Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.
|CEO & Director||3.92yrs||US$1.73m||1.33% |
|Chief Business Officer & CFO||3.92yrs||US$1.03m||0.18% |
|Chief Development Officer||3.92yrs||US$926.04k||0.46% |
|Chief Scientific Officer||3.92yrs||US$1.59m||0.54% |
|Director of Corporate Communications & Investor Relations||no data||no data||no data|
|Head of Regulatory Affairs and QA||no data||no data||no data|
|Senior Vice President of Medical||3.58yrs||US$416.74k||no data|
|Senior Vice President of Development||1.42yrs||no data||no data|
|Director of Finance and Company Secretary||no data||no data||no data|
|Vice President of Finance||no data||US$516.08k||no data|
Experienced Management: KALV's management team is considered experienced (3.9 years average tenure).
|CEO & Director||3.92yrs||US$1.73m||1.33% |
|Independent Director||3.92yrs||US$109.92k||0% |
|Independent Chairman||1.33yrs||US$271.38k||0% |
|Independent Director||5.83yrs||US$109.92k||0% |
|Independent Director||3.92yrs||US$104.92k||0% |
|Independent Director||1.5yrs||US$40.00k||0.056% |
|Independent Director||1.67yrs||US$47.50k||0% |
|Board Observer||5.25yrs||no data||no data|
|Board Observer||5.25yrs||no data||no data|
Experienced Board: KALV's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
KalVista Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: KalVista Pharmaceuticals, Inc.
- Ticker: KALV
- Exchange: NasdaqGM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$303.533m
- Shares outstanding: 17.91m
- Website: https://www.kalvista.com
Number of Employees
- KalVista Pharmaceuticals, Inc.
- 55 Cambridge Parkway
- Suite 901 East
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KALV||NasdaqGM (Nasdaq Global Market)||Yes||New Ordinary Shares||US||USD||Nov 2016|
|4XC1||DB (Deutsche Boerse AG)||Yes||New Ordinary Shares||DE||EUR||Nov 2016|
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product port ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/21 00:08|
|End of Day Share Price||2020/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.